Skip to content
Disclosery

EXANE DERIVATIVES: SABR position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on SABR, newest first. How the timeline and the estimate are built.

EXANE DERIVATIVES held 2,466 SABR shares at 2022-06-30 per its 13F-HR filed 2022-07-12.

the latest 13F is the newest step

  1. period ended2022-06-30
    13F 2,466 shares
    Change vs previous 13F 0 shares

    0.01% of the 13F portfolio, value $14,374.

    13F-HR 0001623883-22-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2022-03-31
    13F 2,466 shares
    Change vs previous 13F +233 shares

    0.01% of the 13F portfolio, value $28,185.

    13F-HR 0001623883-22-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2021-12-31
    13F 2,233 shares
    Change vs previous 13F +1,548 shares

    <0.01% of the 13F portfolio, value $19,181.

    13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2021-09-30
    13F 685 shares
    Change vs previous 13F 0 shares

    <0.01% of the 13F portfolio, value $8,110.

    13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2021-06-30
    13F 685 shares
    Change vs previous 13F not available

    <0.01% of the 13F portfolio, value $7,966.

    13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).